A Short-Term Clinical Evaluation of L-697,661, a Non-Nucleoside Inhibitor of HIV-1 Reverse Transcriptase
| Autor: | Emilio A. Emini, Jeffrey Douglas, Richard J. Whitley, George M. Shaw, John C. Kappes, Ferdinand E. Massari, William I. Lapidus, Michael S. Saag, Kevin W. Anderson, Oscar L. Laskin, Carol Hildebrand, V W Byrnes, William A. Schleif |
|---|---|
| Rok vydání: | 1993 |
| Předmět: |
Chemotherapy
biology Reverse-transcriptase inhibitor business.industry medicine.medical_treatment General Medicine medicine.disease Virology Reverse transcriptase Virus Zidovudine Acquired immunodeficiency syndrome (AIDS) Enzyme inhibitor biology.protein medicine Viral disease business medicine.drug |
| Zdroj: | New England Journal of Medicine. 329:1065-1072 |
| ISSN: | 1533-4406 0028-4793 |
| Popis: | Background The non-nucleoside reverse transcriptase inhibitors are novel antiretroviral agents with selective activity in vitro against human immunodeficiency virus type 1 (HIV-1). They act through direct inhibition of reverse transcriptase and are not incorporated into DNA. Methods We evaluated a pyridinone non-nucleoside reverse transcriptase inhibitor, L-697,661, in separate six-week double-blind trials in patients with HIV-1 infection whose CD4 counts ranged from 200 to 500 cells per cubic millimeter (68 patients) or less than 200 cells per cubic millimeter (67 patients). Eligible patients were randomly assigned to receive L-697,661 orally in one of three doses (25 mg twice a day, 100 mg three times a day, or 500 mg twice a day) or zidovudine (100 mg five times a day). Clinical and laboratory assessments were performed weekly. Viral isolates were obtained from a subgroup of patients before and after treatment and were evaluated for in vitro sensitivity to L-697,661. Results Both L-697,661 and zidovudi... |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|